{
    "clinical_study": {
        "@rank": "85808", 
        "arm_group": [
            {
                "arm_group_label": "Prostate cancer", 
                "arm_group_type": "Other", 
                "description": "Mesenchymal-marker based ferrofluid (c-MET)"
            }, 
            {
                "arm_group_label": "Renal cell carcinoma", 
                "arm_group_type": "Other", 
                "description": "Mesenchymal-marker based ferrofluid (c-MET)"
            }, 
            {
                "arm_group_label": "Bladder cancer", 
                "arm_group_type": "Other", 
                "description": "Mesenchymal-marker based ferrofluid (c-MET)"
            }, 
            {
                "arm_group_label": "Gastric cancer", 
                "arm_group_type": "Other", 
                "description": "Mesenchymal-marker based ferrofluid (c-MET)"
            }, 
            {
                "arm_group_label": "Colorectal cancer", 
                "arm_group_type": "Other", 
                "description": "Mesenchymal-marker based ferrofluid (c-MET)"
            }, 
            {
                "arm_group_label": "Pancreatic cancer", 
                "arm_group_type": "Other", 
                "description": "Mesenchymal-marker based ferrofluid (c-MET)"
            }
        ], 
        "brief_summary": {
            "textblock": "This pilot study will aim to determine whether circulating tumor cells (CTCs) can be\n      captured using the novel cMET based ferrofluid. The primary objective of this pilot study\n      will be to describe the numbers of c-MET expressing cells that can be detected by the c-MET\n      CTC capture technique. These data will be separated by disease site. The investigator will\n      also describe the detection rates of both the c-MET CTC capture and the EpCAM CTC capture\n      techniques in each patient, also separated by disease site."
        }, 
        "brief_title": "Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)", 
        "condition": [
            "Prostate Cancer", 
            "Renal Cell Carcinoma", 
            "Bladder Cancer", 
            "Colorectal Cancer", 
            "Gastric Cancer", 
            "Pancreatic Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urinary Bladder Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Renal Cell", 
                "Colorectal Neoplasms", 
                "Stomach Neoplasms", 
                "Neoplastic Cells, Circulating", 
                "Pancreatic Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Prostate cancer patients will be eligible for inclusion in this study only if all of the\n        following criteria apply:\n\n          1. Histologically confirmed diagnosis of adenocarcinoma of the prostate.  Small cell or\n             neuroendocrine tumors of the prostate are also permitted.\n\n          2. Clinical or radiographic evidence of metastatic disease.\n\n          3. Castrate levels of testosterone (<50 ng/dl)\n\n          4. Enrollment prior to the initiation of a new systemic therapy.\n\n          5. Evidence of disease progression on or following most recent therapy as evidenced by\n             either of the following:\n\n               -  Two consecutive PSA levels greater than the PSA nadir achieved on ADT and most\n                  recent therapy, separated by greater than one week\n\n               -  Radiographic evidence of disease progression as defined by new bone scan lesions\n                  or growth of soft tissue/visceral metastases >1 cm in diameter (2 cm for lymph\n                  nodes).\n\n          6. Age > 18 years.\n\n          7. Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Renal cell carcinoma patients will be eligible for inclusion in this study only if all of\n        the following inclusion criteria apply:\n\n          1. Histologically confirmed diagnosis of invasive renal cell carcinoma (all histologies)\n\n          2. Clinical or radiographic evidence of metastatic disease.\n\n          3. Evidence of disease progression on the current or following the most recent therapy,\n             as evidenced by radiographic evidence of disease progression as defined by a new soft\n             tissue/visceral metastatic lesion.\n\n          4. For clear cell carcinoma, refractory to treatment with VEGF inhibitors as defined by\n             progression on VEGF therapy within 1 year of starting VEGF therapy. For non-clear\n             cell histologies, any line of systemic therapy.\n\n          5. Enrollment prior to the initiation of a new systemic therapy.\n\n          6. Age > 18 years.\n\n          7. Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Bladder cancer patients will be eligible for inclusion in this study only if all of the\n        following inclusion criteria apply:\n\n          1. Histologically confirmed diagnosis of invasive bladder transitional cell carcinoma,\n             adenocarcinoma, squamous cell carcinoma, or small cell carcinoma.\n\n          2. Metastatic disease with either bone or visceral metastatic lesions, or clinically\n             symptomatic with metastatic disease.\n\n          3. Progression with a new metastatic lesion.\n\n          4. Enrollment prior to the initiation of a new systemic therapy.\n\n          5. Age > 18 years.\n\n          6. Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Gastric cancer (including gastroesophageal junction) patients will be eligible for\n        inclusion in this study only if all of the following inclusion criteria apply:\n\n          1. Histologically confirmed diagnosis of invasive gastric adenocarcinoma.\n\n          2. Clinical or radiographic evidence of metastatic disease.\n\n          3. Enrollment prior to the initiation of a new systemic therapy.\n\n          4. Age > 18 years.\n\n          5. Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Colorectal cancer patients will be eligible for inclusion in this study only if all of the\n        following inclusion criteria apply:\n\n          1. Histologically confirmed diagnosis of invasive colorectal adenocarcinoma.\n\n          2. Clinical or radiographic evidence of metastatic disease.\n\n          3. Evidence of disease progression on the current or following the most recent therapy,\n             as evidenced by radiographic evidence of disease progression as defined by new soft\n             tissue/visceral metastases >1 cm in diameter (2 cm for lymph nodes).\n\n          4. Enrollment prior to the initiation of a new systemic therapy.\n\n          5. Age > 18 years.\n\n          6. Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Pancreatic cancer patients will be eligible for inclusion in this study only if all of the\n        following inclusion criteria apply:\n\n          1. Histologically confirmed diagnosis of invasive pancreatic adenocarcinoma.\n\n          2. Clinical or radiographic evidence of metastatic disease.\n\n          3. Enrollment prior to the initiation of a new systemic therapy.\n\n          4. Age > 18 years.\n\n          5. Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n        A patient will not be eligible for inclusion in this study if any of the following\n        criteria apply:\n\n          1. History of intercurrent or past medical or psychiatric illness that would make\n             participation in a blood drawing protocol difficult or not feasible at the discretion\n             of the principal investigator or co-investigator(s).\n\n          2. Treatment with an anthracycline (including mitoxantrone, doxorubicin, epirubicin, and\n             daunorubicin) within 1 week of CTC collection (applicable in prostate and gastric\n             cancer patients), as anthracyclines cause auto-fluorescence of cells."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080650", 
            "org_study_id": "Pro00052149"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Prostate cancer", 
                    "Renal cell carcinoma", 
                    "Bladder cancer", 
                    "Gastric cancer", 
                    "Colorectal cancer", 
                    "Pancreatic cancer"
                ], 
                "intervention_name": "Mesenchymal-marker based ferrofluid (c-MET)", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Prostate cancer", 
                    "Renal cell carcinoma", 
                    "Bladder cancer", 
                    "Gastric cancer", 
                    "Colorectal cancer", 
                    "Pancreatic cancer"
                ], 
                "intervention_name": "Epithelial cell adhesion molecule (EpCAM) ferrofluid", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 31, 2014", 
        "location": {
            "contact": {
                "email": "tian.zhang2@duke.edu", 
                "last_name": "Tian Zhang, MD", 
                "phone": "919-970-3423"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }, 
            "investigator": {
                "last_name": "Andrew J Armstrong, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)", 
        "overall_contact": {
            "email": "tian.zhang2@duke.edu", 
            "last_name": "Tian Zhang, MD", 
            "phone": "(919) 970-3423"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Andrew J Armstrong, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Feasibility as measured by successfully detecting at least one CTC in at least 2 out of 10 subjects within each disease site.", 
            "measure": "Feasibility", 
            "safety_issue": "No", 
            "time_frame": "Only 1 sample will be obtained at a regular clinic visit."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080650"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The difference in the median number of CTCs detected by each of the capture methods (novel and standard) will be calculated.", 
                "measure": "Difference in the median number of CTCs", 
                "safety_issue": "No", 
                "time_frame": "Only 1 sample will be obtained at a regular clinic visit."
            }, 
            {
                "description": "Within each method, the patient will be used as the unit of observation to describe the association of number of detectable CTC cells with the following baseline characteristics: TNM staging, site of metastases (e.g., bone, liver, lymph nodes), Gleason sum (for PC), PSA (for PC), the number of prior hormone therapies (in PC), CEA (for colorectal cancer), the use of previous EGFR inhibitors and KRAS mutation status (for colorectal cancer), HER2 status and prior HER2 treatments (for gastric cancer), CA 19-9 (for pancreatic cancer), and number of prior chemotherapies.", 
                "measure": "Association of the number of detectable CTCs with baseline clinical and pathologic disease characteristics.", 
                "safety_issue": "No", 
                "time_frame": "Only 1 sample will be obtained at a regular clinic visit."
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Prostate Cancer Foundation", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Janssen Diagnostics, LLC", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}